According to a study in the New England Journal of Medicine, Merck & Co.'s Fosamax drug, primarily used for the treatment of osteoporosis in women, is also useful in treating the disease in men. The two-year study, led by a team of researchers from the Oregon Health Sciences University, found that the drug was effective in increasing bone density in men, particularly in the spine and hip. Merck announced earlier this year that it is seeking approval from the US Food and Drug Administration to sell the drug to men. For more information, visit www.merck.com.
CDC Strategies Preventing Hospital-Onset C difficile Effectiveness Inconclusive in Testing
April 15th 2024Hospitals using CDC prevention strategies had different incidences of hospital-associated Clostridioides difficile infection compared to those that didn't, but the reasons are not necessarily the strategies themselves.
Unlocking the Power of AI in Hospital Infection Prevention: A Sustainable Approach to HAIs
April 11th 2024Read on about how, as hospitals grapple with the costly burden of healthcare-associated infections (HAIs), artificial intelligence (AI) emerges as a game-changer in revolutionizing infection prevention strategies.